-
Abduljalil JM, 2020: Laboratory diagnosis of SARS-CoV-2: available approaches and limitations[J]. New Microbes New Infect, 36, 100713-. doi: 10.1016/j.nmni.2020.100713
-
Aziz NA, Corman VM, Echterhoff AK, Müller MA, Richter A, Schmandke A, Schmidt ML, Schmidt TH, de Vries FM, Drosten C, 2021: Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany[J]. Nat Commun, 12, 1-10. doi: 10.1038/s41467-020-20314-w
-
Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, Fry AM, Cannon DL, Chiang C-F, Gibbons A, 2020: Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020[J]. JAMA, 180, 1576-1586.
-
He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W, 2021: Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study[J]. Lancet, 397, 1075-1084. doi: 10.1016/S0140-6736(21)00238-5
-
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL, 2020: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections[J]. Nat Med, 26, 1200-1204. doi: 10.1038/s41591-020-0965-6
-
Majiya H, Aliyu-Paiko M, Balogu VJE, 2020: Seroprevalence of COVID-19 in Niger State[J]. medRxiv, , -. doi: 10.1101/2020.08.04.20168112
-
Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, Lee N, Jung S, Park M-J, Song W, 2020: Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul, Korea[J]. J Korean Med Sci, 35, e311-. doi: 10.3346/jkms.2020.35.e311
-
Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, Smith TC, Bertuzzi S, 2020: Report from the American Society for Microbiology COVID-19 international summit, 23 march 2020: value of diagnostic testing for SARS-CoV-2/COVID-19[J]. mBio, 11, e00722-20.
-
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, de Larrea NF, 2020: Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study[J]. Lancet, 396, 535-544. doi: 10.1016/S0140-6736(20)31483-5
-
Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, Eslami S, Javanmard SH, Shakiba E, Somi MH, 2021: SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study[J]. Lancet Infect Dis, 21, 473-481. doi: 10.1016/S1473-3099(20)30858-6
-
Rostami A, Sepidarkish M, Leeflang M, Riahi SM, Shiadeh MN, Esfandyari S, Mokdad AH, Hotez PJ, Gasser RB, 2021: SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis[J]. Clin Microbiol Infect, 27, 331-340. doi: 10.1016/j.cmi.2020.10.020
-
Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, Ghasempour Z, Heidarzadeh A, Mansournia MA, 2021: Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020[J]. Emerg Infect Dis, 27, 636-638. doi: 10.3201/eid2702.201960
-
Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, Gaggioli G, Giacobbe DR, Bracci-Laudiero L, Magnasco L, 2020: Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors[J]. J Clin Med, 9, 2780-. doi: 10.3390/jcm9092780
-
Watson J, Richter A, Deeks JJb, 2020: Testing for SARS-CoV-2 antibodies[J]. BMJ, 370, m3325-.
-
Yavarian J, Shafiei-Jandaghi N-Z, Sadeghi K, Malekshahi SS, Salimi V, Nejati A, Aja-Minejad F, Ghavvami N, Saadatmand F, Mahfouzi S, 2020: First Cases of SARS-CoV-2 in Iran, 2020: Case Series Report[J]. Iran J Public Health, 49, 1564-.